Novel PCSK9 Drug, Dropped for Risks, Was Effective in Trial

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — Novel PCSK9 inhibitor bococizumab actually prevented cardiovascular events in the higher-risk population studied in the SPIRE-2 trial before the drug's manufacturer halted the development program, researchers said here. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session

< Back to Listings